Hematology Disease Topics & Pathways:
Research, Clinical Trials, Biological therapies, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Workforce, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Checkpoint Inhibitor, Gene Therapy, Therapies, Immunotherapy, immunology, Biological Processes, Technology and Procedures, gene editing, Vaccines
Immunotherapies in Hematology is a rapidly evolving area in hematology. Cutting-edge basic research and clinical findings are presented each year at ASH with broad interest. Understanding of basic immunology is essential to unlock the underpinnings of hematologic disease. Likewise, immunotherapy has revolutionized treatment for patients and is rapidly being applied to malignant and non-malignant diseases to improve outcomes. Emphasis on both basic-translational immunology and applications of immunotherapy is central to improved care in hematologic diseases as fundamentals of immunology, including B/T-cell and thymus function, has broad applications to hematopoietic stem cell transplantation, transfusion medicine, cellular therapy, and novel immune based therapies.
The ASH Poster Walk on Emerging Research in Immunotherapies will present six posters from all fields that are related to “Immunotherapy”: basic-translational research, and clinical research; malignant, and non-malignant. The poster walk will prioritize concept novelty and contribution to the field. The session will also represent junior investigators, gender diversity, institutional diversity, international authors, underrepresented ethnic groups, and various topics (basic-translational, clinical, malignant, non-malignant) in order to represent broad and diverse perspectives in the field.
The following abstracts will be featured in this session:
Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group, Anne Mea Spanjaart
Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6), Olalekan Oluwole